2Xideas AG Has $6.32 Million Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

2Xideas AG lessened its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 26.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 70,654 shares of the medical equipment provider’s stock after selling 24,915 shares during the period. 2Xideas AG owned about 0.10% of Lantheus worth $6,321,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB acquired a new stake in Lantheus during the third quarter worth approximately $25,000. Kestra Investment Management LLC acquired a new stake in shares of Lantheus during the 4th quarter worth $27,000. Summit Securities Group LLC acquired a new stake in shares of Lantheus during the 4th quarter worth $37,000. UMB Bank n.a. increased its position in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 134 shares during the period. Finally, World Investment Advisors LLC acquired a new position in Lantheus in the third quarter valued at about $60,000. 99.06% of the stock is owned by institutional investors.

Lantheus Stock Performance

NASDAQ LNTH opened at $90.92 on Friday. The firm’s fifty day moving average price is $93.31 and its two-hundred day moving average price is $96.12. The stock has a market cap of $6.23 billion, a PE ratio of 15.13 and a beta of 0.38. Lantheus Holdings, Inc. has a fifty-two week low of $58.46 and a fifty-two week high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. As a group, sell-side analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Activity

In related news, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 64,109 shares of company stock valued at $6,110,806 over the last quarter. 2.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on LNTH shares. The Goldman Sachs Group began coverage on shares of Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. B. Riley reduced their price target on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. Truist Financial boosted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. Finally, JMP Securities restated a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $129.43.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.